The document discusses several regulatory reforms for listed medicines in Australia, including:
1. Permitted indications which provide a list of approved health benefit claims for listed medicines and require sponsors to select from this list, improving transparency.
2. An assessed listed pathway which allows pre-market evaluation of efficacy claims, providing access to higher-level health claims.
3. A "TGA assessed" label claim indicating the medicine's efficacy has been evaluated, improving consumer awareness and confidence.
4. Two years of market exclusivity for sponsors who apply for and are approved for new permitted ingredients.
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
Presentation on the review of medicines and medical devices regulation, proposed changes to some definitions and regulation of some products without a medical purpose, reclassification of medical devices (not IVD), Unique Device Identification System and post-market monitoring
Presentation on the background of medicine shortages, definitions, reporting requirements, assessment and management, Section 19A and the compliance framework
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
Presentation on the regulation of software including software as a medical device, proposed regulatory scheme for personalised medical devices, including 3D Printed Devices, proposed changes to the Essential Principles, Conformity Assessment Procedures, and the requirements for devices used in clinical trials, and clarifying the requirements for systems and procedure packs
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Australia
An overview of the Therapeutic Goods Advertising Code (No. 2) 2018 (the Code) followed by a detailed walkthrough of the Code with examples to illustrate the application of the key sections.
Regulatory updates from the TGA Medical Devices Branch - Part 1TGA Australia
Presentation on the review of medicines and medical devices regulation, proposed changes to some definitions and regulation of some products without a medical purpose, reclassification of medical devices (not IVD), Unique Device Identification System and post-market monitoring
Presentation on the background of medicine shortages, definitions, reporting requirements, assessment and management, Section 19A and the compliance framework
SME Assist: Help to navigate the regulatory mazeTGA Australia
Presentation to provide information on TGA’s SME Assist and what the service offers, details on upcoming SME Assist events and information on where to find more help
Regulatory updates from the TGA Medical Devices Branch - Part 2TGA Australia
Presentation on the regulation of software including software as a medical device, proposed regulatory scheme for personalised medical devices, including 3D Printed Devices, proposed changes to the Essential Principles, Conformity Assessment Procedures, and the requirements for devices used in clinical trials, and clarifying the requirements for systems and procedure packs
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
Presentation: Therapeutic Goods Advertising Code (No. 2) 2018TGA Australia
An overview of the Therapeutic Goods Advertising Code (No. 2) 2018 (the Code) followed by a detailed walkthrough of the Code with examples to illustrate the application of the key sections.
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...TGA Australia
An overview of the TGA's implementation of the recommendations made in the Review of Medicines and Medical Devices Regulation and other reforms for the IVD framework
Presentation: Recall of Therapeutic GoodsTGA Australia
An introduction to conformity assessment procedures for medical devices, good manufacturing practice (GMP), some of the problems commonly experienced by sponsors and TGA, and helpful hints.
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...TGA Australia
This presentation highlights some of the changes in Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TGO 101) Order 2019, compared to the previous Order, Therapeutic Goods Order No. 78 – Standard for tablets and capsules.
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
EU Medical Device Regulation: Preparing for Disruptive (yet Incomplete) Regu...YourEncoreInc
The new EU Medical Device Regulation (MDR) represents one of the most disruptive changes to impact the global medical technology sector in recent times.
But with the regulations not finalized, three years to comply, and overall fatigue on the topic, what are the appropriate steps companies should take today to prepare?
In this session, Minnie Baylor-Henry and Jon Lange will briefly outline the current state of EU MDR, its likely impact to medtech company strategy and compliance requirements, and provide appropriate steps companies should take today to prepare.
About Minnie Baylor-Henry, J.D.: Minnie Baylor-Henry, J.D. is a Strategic Advisor to YourEncore and the Medical Devices Practice Lead. Prior to assuming her current role in 2015, she was the Worldwide Vice-President for Regulatory Affairs for Johnson & Johnson’s (J&J) Medical Devices & Diagnostics business.
About Jon Lange: Jon Lange is a Principal in the Advisory Services practice of EY and its EU MDR lead. He has spent 25+ years leading strategic growth initiatives and business transformation change programs for large and mid-tier life science companies.
Devices Sponsor Information Day: 0 - Developments in medical device regulationTGA Australia
Presentations by TGA and Industry (combined) to help sponsors and manufacturers better understand the regulation of medical devices and in-vitro diagnostic medical devices
Presentation: Update from the Complementary and OTC Medicines Branch: Listed ...TGA Australia
This session will provide an overview of the status of reform initiatives arising from the Review of Medicines and Medical Devices Regulation relevant to complementary medicines
TGA Presentation: What’s happening in regulation?TGA Australia
This presentation provides an overview of the Government's response to the Expert Panel Review of Medicines and Medical Devices, with an emphasis on complementary medicines changes.
TGA Presentation: TGA focus and wrap up - What we've done, and what we still ...TGA Australia
An overview of the TGA's implementation of the recommendations made in the Review of Medicines and Medical Devices Regulation and other reforms for the IVD framework
Presentation: Recall of Therapeutic GoodsTGA Australia
An introduction to conformity assessment procedures for medical devices, good manufacturing practice (GMP), some of the problems commonly experienced by sponsors and TGA, and helpful hints.
Presentation Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TG...TGA Australia
This presentation highlights some of the changes in Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TGO 101) Order 2019, compared to the previous Order, Therapeutic Goods Order No. 78 – Standard for tablets and capsules.
Presentation: Updates from the Pharmacovigilance and Special Access BranchTGA Australia
This presentation covers using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program update, international collaboration activities and Adverse Event Management System.
EU Medical Device Regulation: Preparing for Disruptive (yet Incomplete) Regu...YourEncoreInc
The new EU Medical Device Regulation (MDR) represents one of the most disruptive changes to impact the global medical technology sector in recent times.
But with the regulations not finalized, three years to comply, and overall fatigue on the topic, what are the appropriate steps companies should take today to prepare?
In this session, Minnie Baylor-Henry and Jon Lange will briefly outline the current state of EU MDR, its likely impact to medtech company strategy and compliance requirements, and provide appropriate steps companies should take today to prepare.
About Minnie Baylor-Henry, J.D.: Minnie Baylor-Henry, J.D. is a Strategic Advisor to YourEncore and the Medical Devices Practice Lead. Prior to assuming her current role in 2015, she was the Worldwide Vice-President for Regulatory Affairs for Johnson & Johnson’s (J&J) Medical Devices & Diagnostics business.
About Jon Lange: Jon Lange is a Principal in the Advisory Services practice of EY and its EU MDR lead. He has spent 25+ years leading strategic growth initiatives and business transformation change programs for large and mid-tier life science companies.
Devices Sponsor Information Day: 0 - Developments in medical device regulationTGA Australia
Presentations by TGA and Industry (combined) to help sponsors and manufacturers better understand the regulation of medical devices and in-vitro diagnostic medical devices
Presentation: Update from the Complementary and OTC Medicines Branch: Listed ...TGA Australia
This session will provide an overview of the status of reform initiatives arising from the Review of Medicines and Medical Devices Regulation relevant to complementary medicines
TGA Presentation: What’s happening in regulation?TGA Australia
This presentation provides an overview of the Government's response to the Expert Panel Review of Medicines and Medical Devices, with an emphasis on complementary medicines changes.
Expert review of medicines and medical devices regulation: Prescription medic...TGA Australia
This presentation outlines proposals for implementation of several recommendations from the Review of Medicines and Medical Devices Regulation relevant to prescription medicines, including expedited pathways for registration, enhanced post-market monitoring, variations to registered medicines, work sharing with comparable overseas regulators, and the use of overseas assessment reports.
This presentation provides an overview of proposals for implementation of several reform initiatives relevant to prescription medicines, including expedited pathways for registration, enhanced post-market monitoring, variations to registered medicines, work sharing with comparable overseas regulators, the use of overseas assessment reports, and reforms to the orphan drug programs. The information session was held ahead of formal public consultations to provide an early view of the reform proposals to those stakeholders who will be most directly involved in the design of the new regulatory arrangements.
Complementary medicines MMDR reforms: Assessment pathwaysTGA Australia
An overview of the reform initiatives relevant to complementary medicines. Topics include the implementation of recommendations from the Review of Medicines and Medical Devices Regulation.
Presentation: Permitted indications for listed medicines - Completing the app...TGA Australia
The permitted indications reform for listed medicines commenced in March 2018. Are you ready to implement? Do you have questions about selecting indications, the evidence requirements, including indications on your label or transition arrangements? This workshop style session will take a step wise approach to listing a medicine using permitted indications.
Pharmacovigilance and complementary medicines - Regulatory requirementsTGA Australia
Presentation on Pharmacovigilance basics – sponsor obligations, Complementary medicine safety – Regulatory perspective and Special considerations for complementary medicine pharmacovigilance
The challenges of regulating direct to consumer digital medical devicesTGA Australia
Presentation on digital medical devices, the role of the regulator, challenges in applying the framework to digital devices, international approaches and what is the TGA doing
Updates from the Pharmacovigilance and Special Access Branch TGA Australia
Presentation on using new sources of data in Pharmacovigilance, Pharmacovigilance Inspection Program (PVIP) update, International collaboration activities, Adverse Event Management System (AEMS)
Q and A
Manufacturing Investigational Medicinal Products - Legislative and GMP requir...TGA Australia
Presentation on Legislative requirements, specific risks for IMP manufacturing, manufacturing authorisations, PIC/S Guide to GMP PE009-13 and common issues
Update on regulatory reforms from the Scientific Evaluation BranchTGA Australia
Presentation on the latest on variations, Generic Medicines Reform Program, Human cells and tissue regulation (excluded goods), Faecal Microbiota Transplantation and 2D DataMatrix codes for medicines
This presentation highlights some of the changes in Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TGO 101) Order 2019, compared to the previous Order, Therapeutic Goods Order No. 78 – Standard for tablets and capsules.
Presentation: Advertising therapeutic goods to consumers TGA Australia
An overview of the Therapeutic Goods Advertising Code (No. 2) 2018 (the Code) followed by a detailed walkthrough of the Code with examples to illustrate the application of the key sections.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Regulatory updates from the Complementary and OTC Medicines Branch - Listed medicines regulatory reforms
1. Regulatory updates from the Complementary and OTC
Medicines Branch
Listed medicines regulatory reforms
Michael Shum
Director, Business Improvement and Support Section
Complementary and OTC Medicines Branch
2019 ARCS Annual Conference
6 August 2019
2. Objectives of the listed medicines regulatory reforms
Industry Consumers
Transparency
about evidence
Improve the
evidence base
Improve
compliance
Incentivise
innovation
Improve flexibility
and predictability
Simplify the listing
system
Regulatory updates from the Complementary and OTC Medicines Branch
3. Staged implementation
2017
• Online catalogue of permitted ingredients
• Review and appeal rights for ingredient applicants
2018
• Permitted indications for listed medicines
• Assessed listed pre-market evaluation pathway
• 2 year market exclusivity for new ingredients
• Legislated evaluation timeframes
2019
• ‘TGA assessed’ claim
• Risk-based approach to listed medicine variations
Regulatory updates from the Complementary and OTC Medicines Branch
4. Overview of complementary medicines regulatory framework
Australian Register of Therapeutic Goods (ARTG)
AUST L
Listed medicines
NO premarket evaluation
BUT must have:
• GMP
• Permitted ingredients
• Permitted indications
Lower risk
AUST L(A)
Assessed Listed medicines
Premarket evaluation for
efficacy only
(Intermediate level & permitted
indications)
BUT must have
• GMP
• Permitted ingredients
AND can have
• TGA assessed claim
AUST R
Registered medicines
Premarket evaluation for:
• GMP
• Quality
• Safety
• Efficacy
AND can have
• TGA assessed claim
Higher risk
Regulatory updates from the Complementary and OTC Medicines Branch
6. What do permitted indications mean for sponsors?
• Sponsors listing a medicine on the ARTG are only able to use
indications from a list of permitted indications
• “Free text” field is no longer available
• Sponsors must continue to hold supporting evidence for their
medicine indications
• There must not be inconsistency between the indications that
are listed in the Register and on the label
• 3 year transition period for existing listed medicines
Regulatory updates from the Complementary and OTC Medicines Branch
5
7. Transition arrangements – key dates
• All new listed medicines must select permitted
indications
• Sponsors of medicines listed in the ARTG before
6 March 2018 must re-list their medicine using
‘permitted indications’ by 6 March 2021
• Products that have not transitioned by 6 March
2021 will be cancelled from the ARTG.
Changes made before 6 September 2019 can be done free of charge
Regulatory updates from the Complementary and OTC Medicines Branch
8. Permitted indications
Benefits
• Greater transparency for sponsors on what
indications are suitable for listed medicines
• Avoids consumers being misled by inappropriate
indications
• Reduces the rate of inadvertent sponsors non-
compliance
• Sets a clear boundary between the standard
listing and the assessed listed and registration
pathways
Regulatory updates from the Complementary and OTC Medicines Branch
9. Challenges
?
Consumers
TGAIndustry
The list is too long! ‘The TGA is endorsing
pseudo science!!!’
A comprehensive list of
indications suitable for
listed medicines
The list is too short!
• Restricted
representations
• Biomarkers etc..
Regulatory updates from the Complementary and OTC Medicines Branch
10. Transition summary
10319 listed
medicines in the
ARTG
– 4629 using
permitted
indications
(~45%)
– 5693 with
‘standard’ or
specific
indications
Permitted indications commenced 6 March 2018
Regulatory updates from the Complementary and OTC Medicines Branch
11. Nothing is perfect …
Updates to the list of permitted indications since implementation
• New indications
• Clarity and consistency in
requirements
• New requirements
• Correct errors/omissions
Feedback welcome!
Regulatory updates from the Complementary and OTC Medicines Branch 10
12. Questions from industry
Additional guidance/clarification
• When do I need to use evidence qualifiers?
• What evidence do I need if my indications aren’t
qualified?
• How can I combine indications on my medicine
labels?
• How can pregnancy indications be used?
See FAQs on issues raised by industry in relation to permitted indications
Regulatory updates from the Complementary and OTC Medicines Branch
11
13. Questions from industry
Use in advertising
• Am I compliant with the advertising code?
Application requirements for new indications
• What evidence is required for applications for
new indications?
Re-listing process
• How do I do it?
• ELF is……slow
Regulatory updates from the Complementary and OTC Medicines Branch
12
14. Our advice …
• Follow the Permitted indications for listed
medicines guidance
– Keep it simple when modifying or combining
indications
– Use the indication qualifiers from the drop down
lists in ELF
• Start preparing to transition early - you may need
to make other changes (e.g. update GMP)
Regulatory updates from the Complementary and OTC Medicines Branch
13
16. Assessed listed medicine pathway
• Sponsors self-assess the safety (permitted
ingredients) and quality (pre-approved GMP)
of their medicine
• TGA pre-market assessment of scientific
evidence supporting efficacy for the
proposed indications
• Allow higher-level claims which are not
included on the permitted indications list
(eg restricted representations)
Regulatory updates from the Complementary and OTC Medicines Branch
17. Assessed listed medicine pathway
Benefits
• Access to higher level indications than those on
the list of permitted indications
• Encourages industry to improve the standard of
evidence for listed medicines
• Bridges the gap between the existing listed and
registered medicines pathways
Marketing advantage through use of the ‘TGA
assessed’ claim
Regulatory updates from the Complementary and OTC Medicines Branch
19. Feedback from pre-submission meetings
Common discussion points
• Low vs intermediate vs high level indications
• Suitability of suggested indication vs clinical
trial design/evidence:
⁻ e.g. dosing on proposed label vs clinical trial
⁻ e.g. proposed formulation vs clinical trial
formula - what can be changed?
• Dossier requirements
Regulatory updates from the Complementary and OTC Medicines Branch
18
20. Our advice …
• Request a pre-submission meeting
• Identify appropriate indications
• Take care when putting your dossier
together – there are mandatory
requirements
Regulatory updates from the Complementary and OTC Medicines Branch
19
22. TGA assessed claim
• Sponsors of assessed listed medicines and
registered complementary medicines have
the option to use ‘TGA assessed’ claim’
• Indicates that the efficacy of the product
has been assessed for the approved
indications by the TGA
• The medicine label is required to be
approved by the TGA before marketing
• There is an approved symbol and approved
label statement
Regulatory updates from the Complementary and OTC Medicines Branch
21
23. TGA assessed claim
Benefits
• Support consumers to make informed
purchasing decisions
• Improve consumer awareness about
medicines regulation
• Incentive for product sponsors to improve
the standards of evidence for
complementary medicines
Regulatory updates from the Complementary and OTC Medicines Branch
24. TGA assessed claim – consumer insights
Design considerations
• Use simple language (e.g. avoid ‘efficacy’)
• Refer to the Government to build trust
• A symbol is more recognisable than a statement
Regulatory updates from the Complementary and OTC Medicines Branch
25. TGA assessed claim – consumer insights
Unsure about
• Who the TGA is
• How we regulate
• What we have assessed
BUT
• Likely to be a positive influence on purchasing decisions
Regulatory updates from the Complementary and OTC Medicines Branch
26. Access to the TGA assessed claim
• Contact the TGA for the symbol file at
complementary.medicines@health.gov.au.
• Guidance on the process and requirements
now available:
– Location
– Text size
– Font style and colour
– Use in advertising
Regulatory updates from the Complementary and OTC Medicines Branch
25
27. Coming soon….
• Changes to the Advertising Code to
allow use for registered
complementary medicines
• Instrument of approval
Regulatory updates from the Complementary and OTC Medicines Branch
28. Coming soon…
• Support understanding of the TGA
assessed claim and the TGA:
– Education for pharmacists and
pharmacy assistants
– Simpler resources for use by
consumers
– Improve the usability and information
provided on the TGA website for
consumers
Regulatory updates from the Complementary and OTC Medicines Branch
29. Market exclusivity for new ingredients:
Reality of implementation
Regulatory updates from the Complementary and OTC Medicines Branch
28
30. Market exclusivity for new ingredients
• A successful applicant for a new permitted ingredient
may have exclusive use of that ingredient for a 2 year
period
• Use of a protected ingredient in a listed medicine is
restricted to:
the ingredient applicant
other persons nominated by the applicant
• At the end of the exclusivity period, any sponsor can include the
ingredient in their listed medicine included in the ARTG
Regulatory updates from the Complementary and OTC Medicines Branch
31. Eligibility for market exclusivity
Eligible
New ingredients not currently
included in the Permissible
Ingredients Determination, provided:
– not used in, or available for use
in registered medicines
Active or excipient ingredients
Ineligible
New role or a change to any existing
requirements for use eg:
from excipient to an active
ingredient
level of use (e.g. from 0.5% to 1%)
route of administration (e.g. topical
use to oral use)
different plant part or preparation
Regulatory updates from the Complementary and OTC Medicines Branch
32. Questions from industry
• How can I find out if an ingredient is
already under evaluation?
• Will TGA do anything to stop unauthorised
use of ingredients during the exclusivity
period?
• How do I nominate a sponsor to use my
protected ingredient?
Regulatory updates from the Complementary and OTC Medicines Branch
31
33. Our advice…..
• ‘Opt-in’ at the time of making the
application
• Confirm the identity of your
ingredient
Regulatory updates from the Complementary and OTC Medicines Branch
32
34. Reforms on the way 2019- 2020
the way in 2019 - 2020
• Guidance on use of
comparable overseas regulator
reports
• Efficacy monographs for listed
medicines
Regulatory updates from the Complementary and OTC Medicines Branch
33
35. Use of comparable overseas regulators
• Where possible, the TGA makes use of
assessment from other regulators for evaluation
of new substances and products.
• We are developing:
⁻ a list of countries and jurisdictions from whom
TGA will accept reports
⁻ transparent criteria for and guidance for
identifying CORs
⁻ a process for using overseas reports
Regulatory updates from the Complementary and OTC Medicines Branch
34
36. Use of comparable overseas regulators
Benefits for industry
• Faster market access for new
products and ingredients
• Decreased workload through
reduced set of RFI
• Predictability through reduced
approval timeframes
• Greater transparency around
likely acceptance of reports
Benefits for TGA
• Improved efficiency
• Best of both worlds – sovereign
decisions and potential for greater
international harmonisation
Regulatory updates from the Complementary and OTC Medicines Branch
37. Pathways if a report is available
COR-based process
• Evaluation based solely
on the use of COR reports
Combined with
• TGA assessment of
Australian aspects on, eg
the product label
Mixed evaluation
• Evaluation of safety,
quality, and/or efficacy
based on the use of COR
reports
Combined with
• Evaluation of the missing
parameters
Full evaluation by TGA
• Full independent
evaluation of all
parameters: quality,
safety, and/or efficacy.
Can include reports from
overseas agencies not
on the COR list
Increasing evaluation timeframes
Regulatory updates from the Complementary and OTC Medicines Branch
36
38. Application categories for the COR report-based process
Category Description Screening Evaluation
IN1 Evaluation of safety and quality based on evaluation reports
from CORs 40 70
IN2 Evaluation of safety based on evaluation reports from CORs
Independent evaluation of quality by the TGA 40 120
IN3 Evaluation of quality based on evaluation reports from CORs;
or an accepted monograph.
Independent evaluation of safety by the TGA
40 150
IN4 Full evaluation of safety and quality by the TGA 40 180
Regulatory updates from the Complementary and OTC Medicines Branch
39. COR report-based process
• TGA publish list of CORs
Implementation
• Applicants use ‘Criteria for acceptance of COR
reports’ to identify suitable reports
Pre-submission
• Submit COR report and full dossier
• Confirmation that application is eligible for COR
report-based process
Submission
• TGA evaluation focusing on data generated for the
Australian context
Evaluation
Update from the Complementary and OTC Medicines Branch
40. Challenges
Submission through the
COR report-based process
is NOT a rubber stamp…
?
Regulatory
differences
Confidence
building
Types of
reports
Differences in
decisions or approvals
(e.g. for indications)
Regulation
internationally as
foods, medicines,
cosmetics of dietary
supplements
Understanding
regulatory
frameworks and
sharing evaluation
reports
Assessment of safety or
quality or efficacy?
Regulatory updates from the Complementary and OTC Medicines Branch
41. Questions from industry
• When will the COR list and guidance be
available?
• Can TGA get the COR reports for me?
• What if I have a report from a overseas agency
that is not on the list?
• What if the report I have doesn’t meet all of the
criteria for the COR report-based process?
Update from the Complementary and OTC Medicines Branch 40